Skip to main content

Table 2 Patient characteristics TMPRSS3-Group

From: Stable long-term outcomes after cochlear implantation in subjects with TMPRSS3 associated hearing loss: a retrospective multicentre study

Patient*

Gender

Age at implantation

cDNA variant 1**

Protein variant 1

cDNA variant 2**

Protein variant 2

Self-reported duration of HL prior to implantation

Self-reported age of onset HL

Degree HL at time of implantation***

Vestibular function in ear to be implanted****

Reported balance problems prior to implantation

Hearing aid in ear to be implanted

Implanted ear

Implanted device

A1

F

10

c.413C>A

p.(Ala138Glu)

c.916G>A

p.(Ala306Thr)

7.5

2.5

Severe

Normal

−

+

Right

CI24RE (ST)

B1

F

25

c.208del

p.(his70fs)

c.1276G>A

p.(Ala426Thr)

12

13

Profound

Hyporeflexia

+

+

Right

CI24RE (CA)

C1−1

F

4

c.208del

p.(his70fs)

c..916G>A

p.(Ala306Thr)

1

3

Severe

Normal

−

+

Left

CI24RE (CA)

C1−2

 

13

    

10

 

Profound

Normal

 

+

Right

CI512

D1−1

F

5

c.595G>A

p.(Val199Met)

c.936del

p.(Pro313fs)

2.5

2.5

Profound

Normal

−

+

Links

CI24RE (ST)

D1−2

        

Profound

Normal

 

+

Right

CI24RE (ST)

E1

M

17

c.413C>A

p.(Ala138Glu)

c.595G>A

p.(Val199Met)

13

4

Moderate

Normal

−

+

Right

CI422

F1−1

M

6

c.413C>A

p.(Ala138Glu)

c.595G>A

p.(Val199Met)

3.5

2.5

Profound

Normal

−

+

Right

CI522

F1−2

 

9

    

6.5

 

Profound

Normal

 

+

Left

CI24RE (ST)

G1

F

52

c.413C>A

p.(Ala138Glu)

c.916G>A

p.(Ala306Thr)

44

8

Profound

Normal

−

+

Left

CI24RE (CA)

H1

M

29

c.413C>A

p.(Ala138Glu)

c.916G>A

p.(Ala306Thr)

17

12

Profound

Hyporeflexia

−

+

Right

CI522

I1

M

16

c.413C>A

p.(Ala138Glu)

c.595G>A

p.(Val199Met)

<12

<4

Moderate

Normal

−

−

Right

CI632

J1−1

M

4

c.916G>A

p.(Ala306Thr)

c.280G>T

p.(Gly94*)

NA

<4

Profound

NA

−

−

Left

CI632

J1−2

        

Profound

   

Right

CI632

K1

F

46

c.325C>T

Arg109Trp

c.1276G>A

p.(Ala426Thr)

20

26

Profound

Normal

−

+

Left

CI24REH (hybrid L24)

L1−1

F

6

c.595G>A

p.(Val199Met)

c.916G>A

p.(Ala306Thr)

4

2

Profound

Normal

−

+

Left

AB Clarion C−II, Hifocus−1

L1−2

 

7

    

5

 

Profound

  

+

Right

CI24RE (CA)

M1

F

47

c.208del

p.(his70fs)

c.1276G>A

p.(Ala426Thr)

41

6

Profound

Normal

−

+

Left

AB Clarion C−II, Hifocus−1

M2

M

47

c.208del

p.(his70fs)

c.1276G>A

p.(Ala426Thr)

35

12

Profound

Hyperreflexia

−

+

Left

AB Clarion C−II, Hifocus−1

M3

M

44

c.208del

p.(his70fs)

c.1276G>A

p.(Ala426Thr)

24

20

Profound

Normal

−

+

Left

AB HiRes 90 K Advantage, HiFocus Mid−Scala

M4

F

50

c.208del

p.(his70fs)

c.1276G>A

p.(Ala426Thr)

34

16

Profound

Hyperreflexia

−

−

Left

CI612

N1

M

51

c.413C>A

p.(Ala138Glu)

c.413C>A

p.(Ala138Glu)

41

10

Profound

Normal

−

+

Left

CI24M

O1

M

28

c.323−6G>A

p.(Val108fs)

c.413C>A

p.(Ala138Glu)

25

3

Profound

Hyperreflexia

−

+

Right

CI24RE (ST)

O2

M

30

c.323−6G>A

p.(Val108fs)

c.413C>A

p.(Ala138Glu)

26

4

Profound

Hyporeflexia

−

−

Left

CI512

P1

M

54

c.413C>A

p.(Ala138Glu)

c.413C>A

p.(Ala138Glu)

NA

NA

Profound

Normal

−

−

Right

CI24RE (CA)

Q1

M

10

c.46C>T

p.(Arg16*)

c.595G>A

p.(Val199Met)

2

8

Profound

NA

−

+

Right

Med−El concerto flex28

R1−1

M

7

c.916G>A

p.(Ala306Thr)

c.916G>A

p.(Ala306Thr)

2

6

Severe

NA

−

−

Right

CI532

R1−2

 

8

      

Severe

  

−

Left

CI632

S1

F

31

c.413C>A

p.(Ala138Glu)

c.916G>A

p.(Ala306Thr)

15

16

Profound

NA

−

+

Right

CI24REH (hybrid L24)

T1

M

62

c.413C>A

p.(Ala138Glu)

c.1276G>A

p.(Ala426Thr)

22

40

Profound

Normal

−

−

Left

AB HiRes 90 K Advantage, HiFocus Mid−Scala

U1

F

54

c.916G>A

p.(Ala306Thr)

c.316C>T

p.(Arg106Cys)

36

18

Profound

Normal

−

−

Left

AB HiRes 90 K Advantage, HiFocus Mid−Scala

V1

F

13

c.413C>A

p.(Ala138Glu)

c.208del

p.(his70fs)

1

12

Severe

NA

−

−

Left

CI632

W1

M

9

c.413C>A

p.(Ala138Glu)

c.916G>A

p.(Ala306Thr)

9

0

Severe

NA

−

−

Right

CI532

  1. HL hearing loss, NA not available, AB advanced bionics
  2. *Patients C1, E1, H1, l1, M1-4, and O1-2 are previously described by Weegerink et al.
  3. **cDNA and protein nomenclature is based on transcript NM_024022.4
  4. ***According to WHO’s grades of hearing impairment
  5. ****Tested with electronystagmography (ENG) which was performed with vestibular caloric, and rotary chair testing. Patient L1, and M1-M4 were only tested with the rotary chair test